Trabectedin No Better Than Physician’s Choice in Recurrent Ovarian Cancer
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
Decreases in Breast, Cervical Cancer Screening From 2018 to 2020
The prevalence of screening for colorectal cancer remained stable.
Maintenance Rucaparib May Improve Outcomes in Ovarian Cancer
Investigator analysis showed that PFS was improved in the intent-to-treat population with rucaparib, as well as in the HRD population.
Adding Relacorilant to Nab-Paclitaxel May Benefit Some Patients With Ovarian Cancer
Combining relacorilant with nab-paclitaxel improved overall survival in a subset of patients with recurrent, platinum-resistant ovarian cancer.
Appearance of Ovarian Lesions on Ultrasound May Predict Malignancy
The malignancy rate was less than 1% for classic lesions and 32% for nonclassic lesions with blood flow.
Reducing Size of ICG Vials Could Save Cancer Patients and Hospitals Millions of Dollars
To reduce waste and cut costs, researchers recommend making ICG available in a 10 mg vial.
Hispanic Sexual Minorities Least Likely to Undergo Cervical Cancer Screening
Non-Hispanic Black heterosexuals were the group most likely to undergo screening.
Cancer Researchers Aren’t Reporting Quality of Life Outcomes Accurately
Quality of life outcomes were reported favorably for trials that showed no improvement in quality of life.
Adding Radiotherapy to Adjuvant Chemotherapy Improves OS in Stage IV Endometrial Cancer
The greatest benefit was observed when chemotherapy was combined with external beam radiation therapy and vaginal brachytherapy.
Ovarian Cancer Is Not a Silent Killer
Barbara Goff, MD, discusses ovarian cancer and how recognizing symptoms can lead to early detection and reduce misdiagnosis.
Findings May Explain Link Between Obesity and Endometrial Cancer
Fasting insulin, bioavailable testosterone, and sex hormone binding globulin were found to play a role in the relationship between BMI and endometrial cancer risk.
BRCA1/2 Variants Associated With More Cancers Than Previously Thought
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
Fuzuloparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer
Fuzuloparib maintenance significantly delayed the time to disease progression and time to subsequent chemotherapy.
Eponyms in Oncology: HeLa Cells
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of HeLa cells.
Rucaparib Prolongs PFS in BRCA-Mutated, Relapsed Ovarian Cancer
The median duration of response was significantly longer with rucaparib than with standard chemotherapy.
Findings Support Retesting for MMRD at Uterine Cancer Recurrence
Patients who have mismatch repair proficiency in the primary setting may have mismatch repair deficiency at recurrence.
Olaparib Alone, in Combination Does Not Improve PFS in Platinum-Sensitive Ovarian Cancer
Despite the lack of improvement in the overall cohort, olaparib monotherapy and olaparib-cediranib did exhibit activity in a subset of patients with a germline BRCA mutation.
Expanding Eligibility for Genetic Testing Reveals Clinically Actionable Variants
Researchers discovered actionable germline genetic variants in 20% of patients who did not meet genetic testing criteria according to prior guidelines.
Selinexor Maintenance Prolongs PFS in Advanced, Recurrent Endometrial Cancer
Selinexor was associated with a 30% decrease in the risk of progression or death.
Pandemic Tied to Drop in New Cancer Diagnoses
At the start of the pandemic, there was an immediate 34.3% decline in the estimated mean cancer incidence volume.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
Loading... 
Loading...